MARKET

IOVA

IOVA

Iovance Biotherp
NASDAQ
2.640
+0.060
+2.33%
Pre Market: 1.890 -0.75 -28.41% 07:01 08/08 EDT
OPEN
2.605
PREV CLOSE
2.580
HIGH
2.685
LOW
2.560
VOLUME
245.53K
TURNOVER
--
52 WEEK HIGH
12.51
52 WEEK LOW
1.639
MARKET CAP
881.59M
P/E (TTM)
-2.1397
1D
5D
1M
3M
1Y
5Y
1D
IOVANCE BIOTHERAPEUTICS <IOVA.O>: WELLS FARGO CUTS TARGET PRICE TO $14 FROM $18
Reuters · 19m ago
Iovance Biotherapeutics price target lowered to $14 from $18 at Wells Fargo
TipRanks · 22m ago
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC)
TipRanks · 44m ago
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Iovance Biotherapeutics (IOVA)
TipRanks · 1h ago
Wells Fargo Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
TipRanks · 1h ago
Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening
Benzinga · 1h ago
Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Benzinga · 1h ago
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
TipRanks · 2h ago
More
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Webull offers Iovance Biotherapeutics Inc stock information, including NASDAQ: IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.